Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Morgan Stanley Maintains Overweight on Globus Medical, Lowers Price Target to $68

Author: Benzinga Newsdesk | July 15, 2025 08:07am

Morgan Stanley analyst Drew Ranieri maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from $75 to $68.

Posted In: GMED